Bolt Biotherapeutics (BOLT)

NASDAQ
18.79
+0.46(+2.51%)
  • Volume:
    800,925
  • Bid/Ask:
    18.13/37.50
  • Day's Range:
    17.52 - 18.90

BOLT Overview

Prev. Close
18.33
Day's Range
17.52 - 18.9
Revenue
230K
Open
17.8
52 wk Range
17.3 - 43.07
EPS
-1.6
Volume
800,925
Market Cap
682.6M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
248,303
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
36,327,914
Next Earnings Date
Sep 01, 2021
What is your sentiment on Bolt Biotherapeutics?
or
Market is currently closed. Voting is open during market hours.

Bolt Biotherapeutics News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuySellStrong SellSell
Technical IndicatorsBuyStrong BuyNeutralStrong SellBuy
SummaryStrong BuyStrong BuyNeutralStrong SellNeutral

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics Company Profile

Employees
65

Bolt Biotherapeutics, Inc is a clinical-stage immuno-oncology company. The Company is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Its Immune-Stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. The Company’s product candidate BDC-1001 is a human epidermal growth factor receptor 2 (HER2) Boltbody ISAC comprised of a HER2-targeting biosimilar, of trastuzumab conjugated to one of its TLR7/8 agonists, for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. Its Toll-like receptors (TLRs) activate myeloid cells and enable the presentation of tumor-associated neoantigens to cytotoxic T cells.

Read More
  • anything wrong?
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.